Skip to main content
. 2019 Nov 4;14(11):e0224267. doi: 10.1371/journal.pone.0224267

Fig 3. SLFN11 expression is associated with improved survival outcomes in breast, lung, and ovarian cancer patients treated with chemotherapy.

Fig 3

RNA expression and survival data were obtained for primary breast, lung, and ovarian tumors from 4 datasets containing information from 61 breast cancer patients (A/D), 55 and196 lung cancer patients (B/E and C/F, respectively), and 110 ovarian cancer patients (G). Patients were dichotomized into High vs. Low tumor SLFN11 mRNA based on expression above or below the median. Survival analyses were performed for all patients in aggregate in (A-C), and only for patients who received chemotherapy (D-G). Groups were compared by log-rank test.